Evaluation of hand-foot syndrome in the use of capecitabine in the treatment of patients with advanced breast cancer
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.31877/on.2013.22.01 |
Resumo: | Hand-Foot Skin Reaction (HFSR) is a potentially debilitating toxicity side effect mainly associated with 5-FU, liposomal doxorubicin and capecitabine that may have implications in treatment effectiveness and patient quality of life (QoL).In order to prevent secondary effects, it is imperative to evaluate incidence and severity of HFSR in breast cancer patients receiving oral capecitabine chemotherapy, and to assess the impact on the QoL of patients who experience HFSR and their families. This is of major importance of our practice to improve our patients and these families. Education and formation with new strategies will minimize problems caused by this practice. Prospective, non-interventional study. This study was made to 40 female patients with advanced breast cancer whom started palliative chemotherapy with oral monotherapy capecitabine. The education period made to catch patient treatment was of 3 month. All treatments taken were made without any other agents chemotherapy or any other target therapy. Over a 3-month period, 40 female patients starting capecitabine chemotherapy as a treatment for breast cancer (cycles with 14 consecutive days of capecitabine treatment each, with a one week interval between them) were evaluated. Patient and patients’ family HFSR-related QoL was assessed, respectively, using Dermatology Life Quality Index (DLQI) and Family Dermatology Life Quality Index (FDLQI) questionnaires. The family was also assessed since same palliative were not fully independent regarding their daily basics activities.In the evaluation of toxicity dermatology / skin scale was used CTCAE – Version 3.0. Regarding the incidence and severity of HFSR, the study suggested a statistically significant decrease in the percentage of patients with grade 1 toxicity and an increase of toxicity grades 2 and 3, for both hands and feet skin changes and rash/desquamation; around 4% of the nail changes had grade 4 toxicity from the 6th week on. The analysis of the impact of HFSR in QoL showed a significant increase over time of the DLQI scores, while the FDLQI remained constant. The results of this gave us the perspective that patients connect follow went during the treatment decreases the coetaneous toxicity of the HFSR. |
id |
RCAP_92b6d571ec76ce28092afa7d0ab08430 |
---|---|
oai_identifier_str |
oai:oai.onco.news:article/172 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Evaluation of hand-foot syndrome in the use of capecitabine in the treatment of patients with advanced breast cancerAvaliação do síndrome mão-pé na utilização da capecitabina no tratamento das doentes com cancro da mama avançadosíndrome de mão-pé (HFSR)capecitabinaqualidade de vidatoxicidade dermatológicacancro mamaDLQIFDLQIhand-foot skin reaction (HFSR)capecitabinequality of lifedermatological toxicitybreast cancerDLQIFDLQIHand-Foot Skin Reaction (HFSR) is a potentially debilitating toxicity side effect mainly associated with 5-FU, liposomal doxorubicin and capecitabine that may have implications in treatment effectiveness and patient quality of life (QoL).In order to prevent secondary effects, it is imperative to evaluate incidence and severity of HFSR in breast cancer patients receiving oral capecitabine chemotherapy, and to assess the impact on the QoL of patients who experience HFSR and their families. This is of major importance of our practice to improve our patients and these families. Education and formation with new strategies will minimize problems caused by this practice. Prospective, non-interventional study. This study was made to 40 female patients with advanced breast cancer whom started palliative chemotherapy with oral monotherapy capecitabine. The education period made to catch patient treatment was of 3 month. All treatments taken were made without any other agents chemotherapy or any other target therapy. Over a 3-month period, 40 female patients starting capecitabine chemotherapy as a treatment for breast cancer (cycles with 14 consecutive days of capecitabine treatment each, with a one week interval between them) were evaluated. Patient and patients’ family HFSR-related QoL was assessed, respectively, using Dermatology Life Quality Index (DLQI) and Family Dermatology Life Quality Index (FDLQI) questionnaires. The family was also assessed since same palliative were not fully independent regarding their daily basics activities.In the evaluation of toxicity dermatology / skin scale was used CTCAE – Version 3.0. Regarding the incidence and severity of HFSR, the study suggested a statistically significant decrease in the percentage of patients with grade 1 toxicity and an increase of toxicity grades 2 and 3, for both hands and feet skin changes and rash/desquamation; around 4% of the nail changes had grade 4 toxicity from the 6th week on. The analysis of the impact of HFSR in QoL showed a significant increase over time of the DLQI scores, while the FDLQI remained constant. The results of this gave us the perspective that patients connect follow went during the treatment decreases the coetaneous toxicity of the HFSR.O síndrome de mão-pé (HFSR) é um potencial debilitante do efeito secundário associado às doentes submetidas a tratamento de quimioterapia com 5 FU, doxorrubicina lipossómica e capecitabina. Este evento adverso pode ter implicações na efectividade do tratamento e na qualidade de vida (QoL) da doente. Pretendemos avaliar a incidência e severidade do HFSR em doentes com cancro da mama em tratamento com capecitabina (quimioterapia oral) assim como avaliar o impacto na QoL das pacientes que experimentaram HFSR e o impacto da QoL na família/cuidador.É um estudo prospectivo não-interventivo realizado num período de 3 meses, a 40 mulheres que começaram tratamento paliativo de quimioterapia com capecitabina como tratamento para o cancro da mama. As doentes fizeram ciclos de tratamento de 14 dias consecutivos com capecitabina, com uma semana de intervalo entre eles, e foram avaliados os efeitos do HFSR nas doentes e família. Utilizámos respectivamente o índice dermatológico de qualidade de vida (DLQI) e o questionário do índice de qualidade de vida familiar (FDLQI). Em relação à incidência e severidade do HFSR, o estudo refere uma diminuição estatisticamente significativa na percentagem de pacientes com grau 1 de toxicidade e um aumento dos graus de toxicidade 2 e 3, tanto para a erupção/descamação das mãos como dos pés. Cerca de 4% dos doentes tinham alterações nas unhas e tinham um grau de toxicidade de 4 à 6.ª semana de tratamento. A análise do impacto do HFSR na QoL mostrou um aumento significativo dos resultados do DLQI, enquanto os do FDLQI permaneceram constantes.Minimizar o impacto do HFSR na QoL da doente é crucial para a administração de óptimas doses terapêuticas e para a obtenção do maior benefício clínico dos tratamentos com capecitabina.AEOP – Associação de Enfermagem Oncológica Portuguesa2013-11-10info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.31877/on.2013.22.01https://doi.org/10.31877/on.2013.22.01Onco.news; No. 22 (2013): Onco.News Journal; 8-15Onco.News; N.º 22 (2013): Revista Onco.News; 8-152183-69141646-7868reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://onco.news/index.php/journal/article/view/172https://onco.news/index.php/journal/article/view/172/178Direitos de Autor (c) 2023 E Valério , A Rocha , I Silva , C Menesesinfo:eu-repo/semantics/openAccessValério , ERocha , ASilva , IMeneses , C2024-03-16T07:55:26Zoai:oai.onco.news:article/172Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T04:01:24.547240Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Evaluation of hand-foot syndrome in the use of capecitabine in the treatment of patients with advanced breast cancer Avaliação do síndrome mão-pé na utilização da capecitabina no tratamento das doentes com cancro da mama avançado |
title |
Evaluation of hand-foot syndrome in the use of capecitabine in the treatment of patients with advanced breast cancer |
spellingShingle |
Evaluation of hand-foot syndrome in the use of capecitabine in the treatment of patients with advanced breast cancer Valério , E síndrome de mão-pé (HFSR) capecitabina qualidade de vida toxicidade dermatológica cancro mama DLQI FDLQI hand-foot skin reaction (HFSR) capecitabine quality of life dermatological toxicity breast cancer DLQI FDLQI |
title_short |
Evaluation of hand-foot syndrome in the use of capecitabine in the treatment of patients with advanced breast cancer |
title_full |
Evaluation of hand-foot syndrome in the use of capecitabine in the treatment of patients with advanced breast cancer |
title_fullStr |
Evaluation of hand-foot syndrome in the use of capecitabine in the treatment of patients with advanced breast cancer |
title_full_unstemmed |
Evaluation of hand-foot syndrome in the use of capecitabine in the treatment of patients with advanced breast cancer |
title_sort |
Evaluation of hand-foot syndrome in the use of capecitabine in the treatment of patients with advanced breast cancer |
author |
Valério , E |
author_facet |
Valério , E Rocha , A Silva , I Meneses , C |
author_role |
author |
author2 |
Rocha , A Silva , I Meneses , C |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Valério , E Rocha , A Silva , I Meneses , C |
dc.subject.por.fl_str_mv |
síndrome de mão-pé (HFSR) capecitabina qualidade de vida toxicidade dermatológica cancro mama DLQI FDLQI hand-foot skin reaction (HFSR) capecitabine quality of life dermatological toxicity breast cancer DLQI FDLQI |
topic |
síndrome de mão-pé (HFSR) capecitabina qualidade de vida toxicidade dermatológica cancro mama DLQI FDLQI hand-foot skin reaction (HFSR) capecitabine quality of life dermatological toxicity breast cancer DLQI FDLQI |
description |
Hand-Foot Skin Reaction (HFSR) is a potentially debilitating toxicity side effect mainly associated with 5-FU, liposomal doxorubicin and capecitabine that may have implications in treatment effectiveness and patient quality of life (QoL).In order to prevent secondary effects, it is imperative to evaluate incidence and severity of HFSR in breast cancer patients receiving oral capecitabine chemotherapy, and to assess the impact on the QoL of patients who experience HFSR and their families. This is of major importance of our practice to improve our patients and these families. Education and formation with new strategies will minimize problems caused by this practice. Prospective, non-interventional study. This study was made to 40 female patients with advanced breast cancer whom started palliative chemotherapy with oral monotherapy capecitabine. The education period made to catch patient treatment was of 3 month. All treatments taken were made without any other agents chemotherapy or any other target therapy. Over a 3-month period, 40 female patients starting capecitabine chemotherapy as a treatment for breast cancer (cycles with 14 consecutive days of capecitabine treatment each, with a one week interval between them) were evaluated. Patient and patients’ family HFSR-related QoL was assessed, respectively, using Dermatology Life Quality Index (DLQI) and Family Dermatology Life Quality Index (FDLQI) questionnaires. The family was also assessed since same palliative were not fully independent regarding their daily basics activities.In the evaluation of toxicity dermatology / skin scale was used CTCAE – Version 3.0. Regarding the incidence and severity of HFSR, the study suggested a statistically significant decrease in the percentage of patients with grade 1 toxicity and an increase of toxicity grades 2 and 3, for both hands and feet skin changes and rash/desquamation; around 4% of the nail changes had grade 4 toxicity from the 6th week on. The analysis of the impact of HFSR in QoL showed a significant increase over time of the DLQI scores, while the FDLQI remained constant. The results of this gave us the perspective that patients connect follow went during the treatment decreases the coetaneous toxicity of the HFSR. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013-11-10 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.31877/on.2013.22.01 https://doi.org/10.31877/on.2013.22.01 |
url |
https://doi.org/10.31877/on.2013.22.01 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://onco.news/index.php/journal/article/view/172 https://onco.news/index.php/journal/article/view/172/178 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2023 E Valério , A Rocha , I Silva , C Meneses info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2023 E Valério , A Rocha , I Silva , C Meneses |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
AEOP – Associação de Enfermagem Oncológica Portuguesa |
publisher.none.fl_str_mv |
AEOP – Associação de Enfermagem Oncológica Portuguesa |
dc.source.none.fl_str_mv |
Onco.news; No. 22 (2013): Onco.News Journal; 8-15 Onco.News; N.º 22 (2013): Revista Onco.News; 8-15 2183-6914 1646-7868 reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799138187687231488 |